Vaccines of the future

Vaccine

Volumn 29, Issue SUPPL. 4, 2011, Pages

  Nossal, G J V ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Meningococcal vaccine; Polysaccharide vaccines

Indexed keywords

AF 03; ANTINEOPLASTIC AGENT; AS 03; AS 04; BCG VACCINE; CANCER VACCINE; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MALARIA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MIFAMURTIDE; MONOCLONAL ANTIBODY; SPOROZOITE VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELIAC DISEASE; CLINICAL PRACTICE; COLON CANCER; DRUG INDUSTRY; DRUG PROTEIN BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; MALARIA; MEASLES; MELANOMA; MUMPS; PHARMACEUTICAL ENGINEERING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM MALARIAE; PRIORITY JOURNAL; RUBELLA; SPOROZOITE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOUS MENINGITIS; VACCINE PRODUCTION;

AUTOIMMUNE DISEASES; COMMUNICABLE DISEASE CONTROL; HUMANS; NEOPLASMS; VACCINES;

EID: 84859479236     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.089     Document Type: Article

References (21)

1. Cook J., Jeuland M., Whittington D., Poulos C., Clemens J., Sur D., et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008, 26:6305-6316.
2. Meinke A., Henics T., Nagy E. Bacterial genomes pave the way to novel vaccines. Curr Opin Microbiol 2004, 7:314-320.
3. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New Engl J Med 2003, 348(18):1737-1746.
4. Centers for Disease Control and Prevention (CDC) Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59(March (9)):258-261.
5. Webster J., Theodoratou E., Nair H., Seong A.C., Zgaga L., Huda T., et al. An evaluation of emerging vaccines for childhood pneumococcal pneumonia. BMC Public Health 2011, 11(Suppl. 3):S26.
6. Olafsdottir T.A., Lingnau K., Nagy E., Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand J Immunol 2009, 69(3):194-202.
7. McNeil S.A., Halperin S.A., Langley J.M., Smith B., Warren A., Sharratt G.P., et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005, 41(8):1114-1122.
8. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New Engl J Med 2010, 362:289-298.
9. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. New Engl J Med 2008, 359:2521-2532.
10. Beeson J.G., Osier F.H.A., Engwerda C.R. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol 2008, 24:578-584.
11. Kadekoppala M., Holder A.A. Merozoite surface proteins of the malaria parasite: the MSP1 complex and the MSP7 family. Int J Parasitol 2010, 40:1155-1161.
12. Schofield L., Hewitt M., Evans K., Siomos M.A., Seeberger P., Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418:785-789.
13. Hoffmann S.L., Goh L.M.L., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185:1155-1164.
14. Vaughan A.M., Wang R., Kappe S.H. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 2010, 6:107-113.
15. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360:610-617.
16. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
17. Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22:358-366.
18. Parida S.K., Kaufmann S.H.E. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 2010, 22:374-384.
19. Harrison LC. Vaccination for autoimmune and other chronic inflammatory disorders. In Levine MM, editor. New generation vaccines, 4th edn. New York, NY: Informa Health Care. p. 969-81.
20. Tye-Din J.A., Stewart J.A., Dromey J.A., Beissbarth T., van Heel D.A., Tatham A., et al. Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med 2010, 2:41ra51.
21. Sarnaik A.A., Weber J.S. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009, 15:169-173.